IGCS 2020: Does the p53 Protein Have Prognostic Value in Breast Cancer?
Breast Cancer and COVID-19: Treatment Lessons Learned
FDA Issues Alert About Concerns With Atezolizumab Plus Paclitaxel in Triple-Negative Breast Cancer
Oral Paclitaxel and Encequidar Receives FDA Priority Review in Metastatic Breast Cancer
Opioid Use After Surgical Resection of Breast Cancer
Are Circadian Disruption and Breast Carcinogenesis Related?
CHK1 Inhibitor in BRCA Wild-Type Triple-Negative Breast Cancer
Music May Help Women in Chemotherapy for Breast Cancer
NCCN Guidelines Update: Treatment of Hormone-Sensitive Advanced Breast Cancer
NCCN 2020 Congress Series: Breast Cancer With Updates From 2019 San Antonio Breast Cancer Symposium
NCCN Updates in the treatment of HER-2 Positive Breast Cancer
A Multidisciplinary Approach to Individualized Patient Care-Breast Cancer
UC San Diego Moores Cancer Center
Huntsman Cancer Institute at the University of Utah
Yale Cancer Center/Smilow Cancer Hospital
University of Colorado Cancer Center
Talazoparib (Breast Cancer)
(UPDATE) Pertuzumab (Breast Cancer)
(UPDATE) Ribociclib (Breast Cancer)
Sisters Network, Inc.
The Pink Fund
NCCN Guidelines for Patients®
Inflammatory Breast Cancer Research Foundation